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1, I[NTRODUCTION 
G-protein-linked receptors NC 8 large family of cell 
surface receptors charactcriaed by their putative com- 
mon topology of seven membrane-spanning hclixer and 
by their ability to interact with hcteratrimerie G- 
proteins, For several of these receptors, mutagenesis 
and chimeric receptor studies have identified functions 
associated with specific regions of the protein [I]. Of 
particular interest is the mechanism by which receptors 
specify their interaction with the family of CSproteins 
which transduce signals through different effector 
pathways, Previous studies have implicated the third 
cytoplasmic loop (i3 loop) as being important in speci- 
fying G-protein interactions [2-61. The present in- 
vestigation was designed to further address the role of 
the i3 loop and whether the signal transduction 
pathway of a G-protein-linked receptor can be altered 
without affecting its pharmacologic specificity, For this 
purpose, we lx-.z ;&died :he binding and calcium 
mobilizing properties of a chimeric receptor in which 
the i3 loop of the human D2(414) dopamine*receptor 
(which does not mobilize calcium when expressed in 
CM0 cells) was replaced with the analogous portion of 
a calcium mobilizing receptor, the human ml 
muscarinic receptor. 
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2, MATERIALS AND tv¶ETHODS 
The prafcin coding porrion of the human InI muscorinic 
arcrylcholinc reccpror gcnc war clcmxl from human $enomic DNA 
by PCR 171 using prinwr derived from UIC published DNA sequc~~s 
[8,9] (5’~CGGAATTCCC AGCCCCACCT AGCCACCA-3’ and 
5 ’ KiGGGATCCGA GGGATGCAGO AGAC.iGGGAC.3’). 
Amplification was carried out in a 30cyclc, 25jdl reaction containing 
0,5 /rg of human placental DNA (Sigma) using the GenoArnp kit 
(Pcrkin-Elmer Cctus) according to the manufacturer’s rccommcnda- 
tions. The amplified ml receptor DNA was cloned into the mam- 
malinn expression vcc~or pl?Jl-Nco [IO] to produce the ml receptor 
expression plarmid pSRml-9. The ml receptor insert of pSRml-9 
was scquenccd [I II and found to code for the same pcptide sequence 
as one of ~hc published clones (81. 
The coding portion of the cDNA for the short form of the human 
DZ dopaminc receptor (Dz(d14)) was cloned from a AgtlO human retina 
cDNA library by PCR, using primers derived from the published SC- 
quences [12-141 (5’~GCGAATTCAT GGATCCACTG 
AATCTGTCC-3 ’ and 5’.GATAACXTTC AGCAGTCGAG 
~GA’TCTT’T’CAG-3’), Two ,ug of phage DNA was used as template in 
a 30 cycle, 1M) 111 PCR reaction and the amplified Dz(n14) receptor 
fragment was cloned into pBJl-Neo, Tbc DNA sequences of the in- 
serts of two recombinant plasmids were determined and each was 
found to contain a different point mutation introduced by the PCR 
amplification. Therefore, non-mutant restriction fragments from 
each clone were lignted together and rc-cloned into pBJl-Neo to pro- 
duce the D~(4la) receptor expression plasmid pSRD2(4114)-C. 
The Dz/ml receptor chimera was made by the recombinant PCR 
technique [IS]. Primers with sequences 5’-CTTCATTGTC 
ACCCTGCTGG TCTACTGCCG CATCTACCGG GAGA-3’ and 
5 ’ -GAACACGCCG AGAACAATGG CGAGGGTCCG 
ACCCGCCTTC TTCTC-3’ were used in a 10 cycle, 100 pl PCR 
reaction containing 400 ng of linearized pSRml-9 to amplify a frag- 
ment coding for the third cytbpla%iiir loop of the ml receptor fused 
at each end to sequences coding for the homologous portions of the 
fifth and sixth transmembranc segments of the I32 receptor. 35 ng of 
Cells were dc~actrcrl rram cutrurc flwxkx wiih BUTA, pcttcrcrt a~ 
IMMlxa rind rrwxpcndd in I x hindiny burtkr (IO niM Tfis; 120 
mM NaCI: 5 mM KCI; I mhl MyCl:; 2 mbt CaCI~; I.1 mM ascorbic 
acid; pH 7.4) 81 - I x 10bcrlts/ml. CcIh wtrct homogrnincd wirh a 
Pnlylrnn (Brinkman) and the crude nicmbrzinc fraction was pellcfcd 
al I7 000x 8 for IOmin, Membrnncswcrc resuspended in I X bindinp 
buffer and - IO/Q 0r mcmbrans protein rrom CHQ.DZ~.+,~, cells or 
- 2Opg 0r protein rf0m C#O-D:/ml crtlj ws urcrl per I ml binding 
rcacrion. Triplisntc binding reactions were done in I x bindirig hffcr 
for 30 min a[ 37*C, then sroppcd by fillration ~hroiigh glaxsVfibcr 
fillers (Skuron) Uinr wcrc pre.soakcd in 0. I% polyrrhytencinlinc, 
follo~d by a 5 swash with icc~cotclO.1 x binding buffer. Saturation 
binding cxpcriacnrs wcrc done with 8 conccnlraliona Of 
[‘Hjspipcronc (Arncrsham) in Ihc range bctwccn 5 pM and I nM. 
Nonqccific binding was define r: *vilh IOlrM fluphcnazinc. Compeli. 
lion binding cxperimcnls wcrc pcrformvti ::ith 5OQ pM [‘H)spipcrone 
and varying amounts of competing liyand. CompcIing ligends were 
all from Research Biochemicals Inc, 
2.4. Mwswetttettt of fCu”“Ji 
Cells from a single sub-conflucnf 150 cm* ‘T-flask were dclachcd 
with EDTA, resuspended in I>~~lbccco’s phosphate buffered saline 
(D-PBS) containing O.lVo glucose and I 1rM Fura2-AM (Molecular 
Probes Inc.), and incubated for 30 min at 37OC, The cells were then 
centrifuged at 75Oxg for 5 min and resuspended in 40 ml of D-PBS 
containing 0.1070 glucose. The cells were counted and then washed by 
ccntrifugation and resuspension in the same buffer at a concentration 
of - I x 10” cells/ml, A 2 ml aliquo\ of the cell suspension was ccn- 
trifuged and the cells were resuspended in fresh buffer immediately 
prior 10 use. Fluorescence was monitored with a DM%lOOO spec- 
trofluorimetcr (SLM-Aminco) equipped with a cuvztte stirrer. The 
excitation wavelengths were 340 and 380 nm and the emission 
wavelength was 510 nm. ‘The ratio of the intensities of the 
fluorescence at the two excitation wavelengths was used to calculate 
[Ca’*]i as described previously [17]. For each experiment and each 
group of cells, maximum and minimum fluorescence values were 
determined by tile addition of IO mM digitonin followed by 10 tnM 
EGTA. 
3. IRESULTS AND DISCUSSION 
Fig. 1 shows a schematic of the Da/ml receptor that 
was constructed. In contrast o previously published G- 
protein-linked receptor chimeras [S-6,18] , the E&/m 1 
chimera was synthesized entirely by PCR. Since it does 
Fig I, Sift~r~rrre Or ~ltc Wml chiri\r‘ric rwpw. Ttw pcarrian Or rbci 
rcuq3lof clcirlusct rrsm rhc fht4, rrerpw is Intlirn~ml by ihc grcy liur 
and upen clrclcr. The parrion tlcrivcrl Irum the nil fcsctxuf it in- 
ttic;lrctl by Ihc bkisk ltrrc aiitl filled cifclca. Tlw nmirio asitl fc~itlutr 
ni llrc chimera juncliOnt tidr-rittctt circle*) wcrc foniinun 10 boils f+ 
ctticnccr . 
not recjuire restriction sires wirhin the rercprar se- 
quence, the PCR approach is rnueh mom flexible in its 
ability to create DPJA requenccs with desired inserts. 
We were able to insert the entire i3 loop of chc ml 
receptor at exactly the putative ends of rransmcmbrane 
helixes V and VI of the Dz(~IJ) receptor without in- 
troducing any amino acid changes, Howcvcr, the PCR 
amplification produced sequence errors that were 
repaired by fusing the non-mucatcd portions of two 
Dz/ml clones. The use of chcrmostable polytncrascs 
with higher fidelity than Taq polymerasc may improve 
the recovery of chimeras with correct sequences. 
Preliminary studies with CM0 cells showed no detec- 
table specific binding for the muscarinic ligand [3H]- 
QNB or the dopamincrgic ligand [3H]spiperone (data 
not shown). We therefore created cells expressing m 1, 
Dz(~IJ) or Dz/ml receptors by cransfecting CHO-Kl 
cells with an expression vector containing the receptor 
DNA and a neo resistance gene, Transfected cells were 
then selected for G418 resistance, We compared the 
pharmacological profiles of the l&(414) and Dz/ml 
receptors to see what effect, if any, the substitution of 
the i3 loop from the ml receptor had upon the chimeric 
receptor’s affinity for dopaminergic ligands. Shown in 
Fig. 2 is a representative Scatchard plot of the binding 
of [3H]spiperone to crude membranes prepared from 
cells expressing either the l&(414) or the Dzml receptor. 
The & of 65 rt 12 pM (mean f SE (n = 3); Bnlax== 4.0 
f 1 .l pmol/mg protein) determined for the D2(414) 
receptor agrees well with a previous determination of 
the Kd for [3H]spiperone for the rat D2(415) receptor 
[19], The Da/ml receptor shows a modest, but 
statistically significant (P~0.05; t-test), decrease in 
LHjspiperone affinity (Kd= _250~ 10 pM (n = 3); 
max = 3.8 f 0.6 pmol/mg protein), Next, we tested the 
binding affinities of six dopaminergic ligands in a com- 
a 
petition binding assay with [‘HJspiperone. The results 
of 3 indcprndcirt competition assays are summarized in 
Table 1. Tkcrc was IIO difference in KI’S of N-0434, 
C- )-sulpiridc and SKF-38393 for the %)ICJI~~ and &)r/ml 
receptor and rrlttrough statistically significant ($<0.05; 
r-test), the differences in the #I values for dopaminc, 
fluphenazinc and SCM~23390 were small. 
Preliminary studies with non-tram&ted CM0 cells 
indicated that [Ca”“]i was unaltered by carbachol (100 
rrM) or dopamine (1 mM) (data not shown). Activatian 
of the human ml receptor has been previously shown 
to cause phospfiatidylinositol hydrolysis and elevation 
of [Ca”2]i [20]. When we expressed the human ml 
rccepror in CHO cells, it bound [“H]QNB with a K,I OF 
81 pM and elevated [Ca+‘]i n a dose-dependent man- 
ner in response to carbachol (data not shown). B2 
receptors, on the other hand, are classically associated 
with inhibition of adenylate cyclase [21] and thus 
thought to couple to a Cii-type G-protein. Both forms 
of the Dz receptor have been shown to inhibit CAMP 
accumulation when expressed in the appropriate cell 
lines [ 13,22,25 1, However, there have been some 
al dapaminc was blocked by the tlapnmine antagonist 
fluphennsinc (Fig. 3C), 
Our result, that the Dl/mI ckimcric rdccptor ctnins 
the pharmacologic sgccificity of a Da receptor and 
rlcvatea [Cn”*]r in rcsponxe to clapamine, is significant 
in two respects, First, it provides additional support for 
the idea char the i3 loop of Onpratcin-linked receptors 
is important in determining the specificity of Gprotcin 
interaction, Second, ir suggests the possibility of a 
generic strnrcgy for directing members OF the 0. 
prorein~linkcd receptor family to elevetc [Ca’2]i when 
this ia not their native or preferred signal transduction 
pathway, Such an approach may prove uscfui For 
several purposes, For example, ‘orphan’ receptors, i.e. 
those receptors identified by homology to known rcccp- 
tars but For which the natural agonist is unknown, 
could be engineered to elevate [Ca*2]i by the approach 
illustrated here, The calcium assay could then be used 
to identify agonists for the ‘orphan’ receptor. Chimeric 
receptors could also be important tools for drug 
discovery, where the idcnriFication of families of recep- 
tor subtypes has increased the need for inexpensive and 
facile assays for testing large numbers of potential drug 
candidates. Typically, radioisotopic ligand binding and 
second messenger assays are employed in screening 
drug candidates for their interaction with G-protein- 
linked receptors. But if the nucleotide sequence of a 
receptor is known, a chimeric receptor similar to the 
&/ml receptor can be created quite easily using PCR. 
The [Ca*2]i response is rapid, robust and likely to be 
automatable. Thus, it may be possible to screen large 
Table I 
Kt values GM) for dopaminergic lignnds 
Campctitot DW 14) Reccptoi D2/m1 Receptor 
I\‘i GuM) 95% C.L. lip f/W 95% C.L. 
Fluphcnazinc* 0.0031 (0.0016, 0.0057) 0.0072 (0.0053, 0.0098) 
N-0434 0,021 (0.010, 0.042) 0.027 (0.012, 0.058) 
(-)Sulpiride 0,028 (0.015, 0.054) 0.045 (0.011, 0.180) 
Dopamine* 60 (4.9, 7.4) 2,I (0.93, 4.63) 
SCM.23390’ 2>1 (1.5, 3.0) 3.6 (2.4, 5.3) 
SKF-38393 21 (8.8, 5 1) 36 (19, 70) 
* Difference between Dz and D,/ml receptor is statistically significant (PCO.05; f-test) 
Specific binding of [‘Hlspiperone (0.5 nM) at twelve different concentrations of competing ligand was determined in triplicate. ICso’s were deter- 
mined by analysis with the program ALLFIT [26] and Ki’s were computed using the Chcng-Prusoff equation 1271. Kd values for [3Hlspiperone, 
which differed between the two receptors, are given in the text. Values are the anti-log or the mean log Ki from three separate xperiments and 
99% confidence intervals calculated from the standard deviation of the log Ki 
89 
Fig. 3. Effect of dopamine on [Cn*$ in Pura-2 loaded CHO cells. 
(A) %plamine (1 mM final concentration) was added ~a CI*(O cells 
expressing Datrld, receptors at rhc indicated time, (B) Various conccn- 
trations of dopnminc were added nr the time indicnccd ro Cl-i0 cells 
expressing DZ/ml receptors, The final concentrations of dopamine 
from the bottom to the top curve were 0, I, I, 10, 100, IOOO~~M. (C) 
Cf-IO cells expressing D2/ml receptors were prc-incubalctl with or 
wirhaut lO/rM fluphcnazinc for 2 min followed by addition of 1OpM 
dopamine aI [hc indicated time, 
numbers of compounds as agonists or antagonists of 
any previously cloned member of the G-protein-linked 
receptor family and avoid the hazards and costs 
associated with the use of radioisotopes. 
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